Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TCM injection plus routine western medicine for severe pandemic influenza A(H1N1)
ChiCTR-TRC-10000814Phase 4Recruiting
- Sponsor
- Institute of Basic Research in Clinical Medicine
- Start
- Jan 2010
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of Reduning, andrographolide sulfonate and salvia miltiorrhiza in Influenza A virus subtype H1N1 infection (H1N1) (2 arms), sponsored by Institute of Basic Research in Clinical Medicine. Primary endpoints: fever clearance time, conversion of critical condition and 1 more. Started Jan 2010; status: recruiting.
02
Drugs
Reduningandrographolide sulfonatesalvia miltiorrhiza
03
Conditions
Influenza A virus subtype H1N1 infection (H1N1)
Beyond the preview
Go deeper on ChiCTR-TRC-10000814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-10000814.